Denmark’s Genmab says that it has received a milestone payment from partner Roche after the Swiss healthcare giant filed an Investigational New Drug application in the USA for an antibody developed under the companies’ collaboration.

This is the fourth antibody developed under the firms’ pact to have entered the clinic, noted Genmab’s chief executive Lisa Drakeman, and involves a compound that Roche and its majority-owned subsidiary Genentech are developing which selectively blocks the interaction of the OX40 ligand and its receptor. The companies are evaluating the antibody for the treatment of asthma.

Genmab did not disclose the size of the milestone payment but noted that it does not influence its financial guidance for 2007. Ms Drakeman added that “this achievement is a testament to the skill of Genmab's pre-clinical development team who work carefully to select the best product candidates and Roche's dedicated focus on progressing them to market".